Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Q1 2026 Total Revenue and Financial Results Overview
GILD logo

Gilead Sciences Raises 2026 Sales Guidance to $30.4 Billion as HIV Portfolio Surges 10%

GILD8-KFiling Date: 5/7/2026
Gilead Sciences, Inc.
Description

What this story covers

Gilead Sciences reported strong Q1 2026 results, with total revenue reaching $7.0 billion. Growth was driven by a 10% increase in HIV sales and robust oncology performance, leading the company to raise its full-year sales and earnings guidance.

Story snapshot

CompanyGilead Sciences, Inc.
TickerGILD
VariantStandard detailed
Duration6:14
Filing type8-K
PeriodQ2 2026
IndustryHealthcare & Pharmaceuticals
Accession0000882095-26-000022
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in